Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928834 | 1.00 | SMN1; SMN2 (0.35) | SMN1; SMN2CYP2C19MEN1KMT2AMAPT | |
| SCHEMBL6926316 | 0.78 | CTSK (0.38) | SMN1; SMN2CYP2C19MEN1KMT2AMAPT | |
| SCHEMBL250445 | 0.74 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP2C19KMT2AMAPTMTOR | |
| Hydrochloric Acid SCHEMBL565469 | 0.73 | SMN1; SMN2 (0.39) | SMN1; SMN2CYP2C19MEN1KMT2AMAPT | |
| SCHEMBL6928840 | 0.69 | AOC3 (0.34) | MEN1KMT2A | |
| SCHEMBL31426820 | 0.69 | MAPT (0.51) | CYP2C19MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6724867 | 0.68 | MTOR (0.58) | SMN1; SMN2CYP2C19MEN1KMT2AMAPT | |
| SCHEMBL10582023 | 0.68 | SMN1; SMN2 (0.46) | SMN1; SMN2CYP2C19KMT2AMAPTMTOR | |
| SCHEMBL8058900 | 0.65 | SMN1; SMN2 (0.43) | SMN1; SMN2CYP2C19MTORRAB9AGRM7 | |
| SCHEMBL8119644 | 0.65 | CYP3A4 (0.53) | SMN1; SMN2CYP2C19MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515126-B2 | Chemical intermediate in biosynthesis of neurokinin receptor antagonist | MERCK SHARP & DOHME LTD. | 2003-02-04 | — | — | US | disclosed |
| US-20010029297-A1 | Chemical synthesis of spirocyclic piperidines by double ring-closing metathesis | MERCK SHARP & DOHME LTD. (GB) | 2001-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010029297-A1 | Chemical synthesis of spirocyclic piperidines by double ring-closing metathesis | CTPS1, DHPS, CTPS2 | SMN1; SMN2 3355/4885CYP2C19 69/4885MEN1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.